Tandem Diabetes Care, Inc.

NASDAQ:TNDM

Medical - Devices

Healthcare
$17.05 +1.53%

+$0.24 today

Market cap
$1.19B
Beta
1.57
P/E (TTM)
-11.3
EPS (TTM)
-$1.38
52W Low $9.98High $29.65

Volume 2.35M

Average 2.43M

TNDM Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Tandem Diabetes Care, Inc.NASDAQ: TNDM

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $110.43M fell 4.8% year over year, ahead of the -21.4% change in trailing-twelve-month cost of revenue. Sequentially, it fell 10.2% from the prior quarter. Over 3 fiscal years it compounded at +7.6% a year.

Context

  • Cost of revenue amounted to 47.7% of revenue in FY2025, down 0.2 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -4.8% holds above the trailing-twelve-month pace of -21.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$110.43M-10.2% QoQ
Last fiscal yearDec 2025
$483.89M+7.4% YoY
LTMMar 2026
$463.14M-21.4% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.8%——
1 year+7.4%——
3-year CAGR+7.6%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
483.89M USD
Year-over-year change
+7.4%
4-year CAGR
+10.3%

Cost of Revenue vs competitors

How TNDM compares with its peers on the latest reported figures

  • TNDM's LTM Mar 2026 cost of revenue of $463.14M is the 4th highest of the 8 companies compared; the peer median is $86.73M.
  • Its year-over-year change of -21.4% is the 6th highest of 7, against a peer median of +10.0%.
  • Cost of revenue amounts to 45.1% of revenue for TNDM, versus a peer median of 40.2%.
TNDM Competitors Peer median
Cost of Revenue for TNDM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DXCMDexCom, Inc.LTM Jun 2026$1.86B +5.2%+21.9%37.5%
MMEDMiniMed Group, Inc. Common StockLTM Jul 2026$1.49B —+14.9%46.2%
PODDInsulet CorporationLTM Jun 2026$883.1M +27.9%+15.4%28.9%
TNDMTandem Diabetes Care, Inc.LTM Mar 2026$463.14M -21.4%+7.6%45.1%
MNKDMannKind CorporationLTM Mar 2026$86.73M +14.8%+2.1%24.0%
BBNXBeta Bionics, Inc.LTM Mar 2026$47.24M +46.8%—42.8%
SENSSenseonics Holdings, Inc.LTM Mar 2026$19.51M -11.2%+12.6%47.9%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$0 -100.0%——
MMEDVMiniMed Group, Inc.—— ———
Peer median (excluding TNDM) $86.73M+10.0%+14.9%40.2%

Competitors are the stored peer set for TNDM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue702.8M801.22M747.72M940.2M1.01B
Cost of Revenue326.58M388.23M380.03M450.63M483.89M
Gross Profit376.22M412.99M367.69M489.57M530.85M
Gross Margin53.5%51.5%49.2%52.1%52.3%
Research & Development92.05M170.15M248.42M198.88M174.84M
Selling, General & Admin261.51M335.68M352.5M389.82M434.13M
Operating Expenses353.56M505.83M600.92M588.7M608.97M
Depreciation & Amortization13.85M14.33M15.72M158K17.67M
EBITDA34.06M(74.21M)(196.46M)(99.13M)(174.7M)
EBITDA Margin4.8%-9.3%-26.3%-10.5%-17.2%
Operating Income22.65M(92.85M)(233.23M)(99.13M)(78.12M)
Operating Margin3.2%-11.6%-31.2%-10.5%-7.7%
Interest Income674K6.06M22.86M17.99M9.09M
Interest Expense6.04M6.21M9.88M7.42M7.91M
Other Income / Expenses(6.75M)(4K)12.98M7.26M(122.15M)
Income Before Tax15.9M(92.85M)(220.25M)(91.87M)(200.27M)
Pre-Tax Margin2.3%-11.6%-29.5%-9.8%-19.7%
Income Tax Expense335K1.74M2.36M4.16M4.44M
Net Income15.57M(94.59M)(222.61M)(96.03M)(204.71M)
Net Margin2.2%-11.8%-29.8%-10.2%-20.2%
EPS (Basic)0.25(1.47)(3.43)(1.47)(3.04)
EPS (Diluted)0.24(1.47)(3.43)(1.47)(3.04)
Weighted Avg Shares63M64.15M64.9M65.45M67.29M
Weighted Avg Shares (Diluted)64.35M64.15M64.97M65.45M67.29M

Tandem Diabetes Care, Inc.

NASDAQ:TNDM

Intrinsic Alpha fair value

Locked

Current Price

$17.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.